Gain Therapeutics (GANX) Insider Trading & Ownership $1.50 +0.01 (+0.62%) (As of 10:26 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Gain Therapeutics (NASDAQ:GANX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.70%Number OfInsiders Buying(Last 12 Months)4Amount OfInsider Buying(Last 12 Months)$201,084.00Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$506.76 GANX Insider Buying and Selling by Quarter Ad Behind the MarketsOur #1 Ticker for the Rare "Retirement Window"We've only seen this happen three times in the past 20 years... And every time - like clockwork - it's minted an entire new class of millionaires.Click here for our #1 "Retirement Window" Stock >>> Gain Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/9/2024Gene MackCEOBuy14,400$1.01$14,544.00 8/9/2024Khalid IslamChairmanBuy50,000$1.00$50,000.00 7/1/2024Eric I RichmanDirectorBuy17,000$1.22$20,740.00 3/28/2024Jeffrey Scott RileyDirectorBuy30,000$3.86$115,800.00 12/21/2023Matthias AlderCEOSell206$2.46$506.76 (Data available from 1/1/2013 forward) GANX Insider Trading Activity - Frequently Asked Questions Who is on Gain Therapeutics's Insider Roster? The list of insiders at Gain Therapeutics includes Eric I Richman, Gene Mack, Jeffrey Scott Riley, Khalid Islam, and Matthias Alder. Learn more on insiders at GANX. What percentage of Gain Therapeutics stock is owned by insiders? 11.70% of Gain Therapeutics stock is owned by insiders. Learn more on GANX's insider holdings. Which Gain Therapeutics insiders have been buying company stock? The following insiders have purchased GANX shares in the last 24 months: Eric I Richman ($20,740.00), Gene Mack ($14,544.00), Jeffrey Scott Riley ($115,800.00), and Khalid Islam ($50,000.00). How much insider buying is happening at Gain Therapeutics? Insiders have purchased a total of 111,400 GANX shares in the last 24 months for a total of $201,084.00 bought. Which Gain Therapeutics insiders have been selling company stock? The following insider sold GANX shares in the last 24 months: Matthias Alder ($506.76). How much insider selling is happening at Gain Therapeutics? Insiders have sold a total of 206 Gain Therapeutics shares in the last 24 months for a total of $506.76 sold. Gain Therapeutics Key ExecutivesDr. Khalid Islam Ph.D. (Age 69)Founder & Chairman Compensation: $75kMr. Matthias Alder LIC. IUR. (Age 59)LL.M., President, CEO & Director Compensation: $593kMr. Gene Mack M.B.A.Chief Financial OfficerDr. Manolo Bellotto Ph.D. (Age 53)GM & Chief Strategy Officer Compensation: $251.99kDr. Joanne Taylor Ph.D.Senior Vice President of ResearchDr. Terenzio Ignoni Pharm.D.Senior Vice President of Technical OperationsDr. Jonas Hannestad M.D.Ph.D., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies: Hookipa Pharma Insider Selling Passage Bio Insider Selling Elutia Insider Selling Atyr PHARMA Insider Selling Kodiak Sciences Insider Selling Invivyd Insider Selling Immunic Insider Selling OptiNose Insider Selling Century Therapeutics Insider Selling Eton Pharmaceuticals Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: This Is the Top Large-Cap Stock Insiders Are BuyingMatador Resources Insiders Keep Buying Its Stock, Should You?Top 3 Small-Cap Stocks Insiders Are Buying Right Now3 Small Cap Stocks That Insiders Are BuyingMGM Insiders Bet Big on Its Undervalued Stock This page (NASDAQ:GANX) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredNew President Kamala warningFinancial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on ...Stansberry Research | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Gain Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
